Company News: Novartis

Share this article:
Novartis and its vaccines/diagnostics division agreed to pay a $72.5-million settlement to resolve off-label marketing allegations involving cystic fibrosis drug TOBI. Novartis and predecessor Chiron Corp., according to a Justice Department statement, allegedly caused false claims to be submitted to the VA and other federal health programs between January 2001 and July 2006 by marketing the inhaled antibiotic for unapproved uses. To resolve their respective claims, the US is receiving $43.5 million and states $29 million. In connection with the qui tam suit, brought under the False Claims Act, three whistleblowers will share $7.825 million.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.